JNJJanssen Research & Development, LLCNot started yet
A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
Multiple Myeloma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 1,000 (planned)
- Started
- Dec 14, 2026
- Main results expected
- Jan 11, 2037
- Fully finished
- Jan 11, 2037
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS)
Measured over: Up to approximately 10 years
Percentage of Participants Achieving 12-Month Minimal Residual Disease (MRD)-Negative Complete Response (CR)
Measured over: Up to approximately 12 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07903272 · record last updated 2026-11-04 · checked 2026-11-09 15:47 UTC